Recombinant Human IL-17B Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00432P-100UG

Human IL-17B on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human IL-17B Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00432P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human IL-17B Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gln21-Phe180. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q9UHF5 |
Target Symbol | IL-17B |
Species | Human |
Expression System | HEK293 |
Tag | C-hFc |
Expression Range | Gln21-Phe180 |
Mol. Weight | The protein has a predicted MW of 44.91 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human IL-17B, hFc Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Anti-IL-17B Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. |